CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)

On May 15, 2024, CASI Pharmaceuticals (NASDAQ: CASI) announced that the FDA has cleared their Investigational New Drug (IND) application for CID-103.

Rhea-AI Summary

On May 15, 2024, CASI Pharmaceuticals (NASDAQ: CASI) announced that the FDA has cleared their Investigational New Drug (IND) application for CID-103. This clearance supports a phase 1/2 study of CID-103 in adults with chronic Immune Thrombocytopenia (ITP), a serious autoimmune disorder. The IND application was submitted on April 12, 2024, and the FDA's approval letter was received on May 13, 2024.

CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody that has shown promising preclinical efficacy and safety profiles. Dr. Wei-Wu He, CEO of CASI, highlighted the potential of CID-103 to become a new therapeutic option for ITP, aiming to reduce the disease burden for patients.

Positive

• FDA clearance of the IND application for CID-103.
• Preclinical efficacy and safety profile of CID-103 looks promising.
• Potential new therapeutic option for patients with chronic ITP.
• Approval supports the commencement of a phase 1/2 study.

Negative

• No concrete data on clinical efficacy or safety from human trials yet.
• Potential risks and uncertainties inherent in early-stage clinical trials.
• Financial costs associated with clinical trials may impact future earnings.

Argus Session date unavailable

+3.15% session move Open Argus

Details

News Market Reaction – CASI

The recorded move for CASI in the trading session of this news was +3.15%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BEIJING, May 15, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced today the following: On April 12, 2024 CASI submitted the IND application to the FDA for CID-103 to support a phase 1/2 study of CID-103 in adults with chronic Immune Thrombocytopenia (ITP). On May 13, 2024 CASI received a letter from FDA indicating that study may proceed.

CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique. Epitope that has demonstrated encouraging preclinical efficacy and safety profile compared to other anti-CD38 monoclonal antibodies.

Dr. Wei-Wu He, CEO of CASI, said "ITP is a serious autoimmune blood disorder characterized by autoantibody-mediated platelet destruction and impaired platelet production, leading to thrombocytopenia and an increased risk of life-threatening bleeding episodes. We are excited to advance this program into clinical development as CID-103 has the potential to represent a new therapeutic option to help alleviate the disease burden in this patient community."

About CASI Pharmaceuticals  

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market, leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. More information on CASI is available at www.casipharmaceuticals.com.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on The Nasdaq Capital Market if we fail to satisfy applicable continued listing standards; the volatility in the market price of our ordinary shares; the risk of substantial dilution of existing shareholders in future share issuances; the difficulty of executing our business strategy on a global basis including China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; legal or regulatory developments in China that adversely affect our ability to operate in China, our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency, PRC National Medical Products Administration, or other regulatory authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; the risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the risks associated with our product candidates, and the risks associated with our other early-stage products under development; the risk that result in preclinical and clinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; our ability to protect our intellectual property rights; the lack of success in the clinical development of any of our products; and our dependence on third parties; the risks related to our dependence on Juventas to conduct the clinical development of and to partner with us to co-market CNCT19; risks related to our dependence on Juventas to ensure the patent protection and prosecution for CNCT19; risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); risks relating to interests of our largest shareholder and our Chairman and CEO that differ from our other shareholders; and risks related to the development of a new manufacturing facility by CASI Pharmaceuticals (Wuxi) Co., Ltd. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided herein is as of the date of this announcement, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

COMPANY CONTACT:
Rui Zhang
CASI Pharmaceuticals, Inc.
240.864.2643
ir@casipharmaceuticals.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-receives-fda-clearance-on-the-investigational-new-drug-ind-application-for-cid-103-in-immune-thrombocytopenia-itp-302145848.html

SOURCE CASI Pharmaceuticals

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What recent FDA clearance did CASI Pharmaceuticals receive?

CASI Pharmaceuticals received FDA clearance for their IND application for CID-103 in adults with chronic Immune Thrombocytopenia (ITP).

When did CASI Pharmaceuticals submit the IND application for CID-103?

CASI Pharmaceuticals submitted the IND application for CID-103 on April 12, 2024.

What is CID-103?

CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody developed by CASI Pharmaceuticals.

What is the significance of FDA clearance for CASI's IND application?

The FDA clearance allows CASI Pharmaceuticals to proceed with a phase 1/2 study of CID-103 in adults with chronic ITP.

What potential therapeutic area is CID-103 targeting?

CID-103 is targeting chronic Immune Thrombocytopenia (ITP), an autoimmune blood disorder.